Loading...

Santhera Pharmaceuticals Holding

DB:S3F
Snowflake Description

Exceptional growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
S3F
DB
CHF168M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. The last earnings update was 128 days ago. More info.


Add to Portfolio Compare Print
  • Santhera Pharmaceuticals Holding has significant price volatility in the past 3 months.
S3F Share Price and Events
7 Day Returns
0.9%
DB:S3F
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-13.7%
DB:S3F
-10.6%
DE Biotechs
-6.2%
DE Market
S3F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Santhera Pharmaceuticals Holding (S3F) 0.9% 8.2% 164.7% -13.7% -78.6% 353%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • S3F underperformed the Biotechs industry which returned -10.6% over the past year.
  • S3F underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
S3F
Industry
5yr Volatility vs Market

Value

 Is Santhera Pharmaceuticals Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Santhera Pharmaceuticals Holding to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Santhera Pharmaceuticals Holding.

DB:S3F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:S3F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 18%) (32.17%))
1.556
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.56
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.556 * 5.96%)
9.5%

Discounted Cash Flow Calculation for DB:S3F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Santhera Pharmaceuticals Holding is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:S3F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CHF, Millions) Source Present Value
Discounted (@ 9.5%)
2019 -67.00 Analyst x1 -61.19
2020 -55.00 Analyst x1 -45.87
2021 25.00 Analyst x1 19.04
2022 251.00 Analyst x1 174.59
2023 517.00 Analyst x1 328.41
2024 768.21 Est @ 48.59% 445.65
2025 1,030.03 Est @ 34.08% 545.69
2026 1,276.47 Est @ 23.93% 617.58
2027 1,491.12 Est @ 16.82% 658.84
2028 1,667.67 Est @ 11.84% 672.92
Present value of next 10 years cash flows CHF3,355.67
DB:S3F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CHF1,667.67 × (1 + 0.23%) ÷ (9.5% – 0.23%)
CHF18,026.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CHF18,026.83 ÷ (1 + 9.5%)10
CHF7,274.00
DB:S3F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CHF3,355.67 + CHF7,274.00
CHF10,629.67
Equity Value per Share
(CHF)
= Total value / Shares Outstanding
= CHF10,629.67 / 10.61
CHF1002
DB:S3F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:S3F represents 0.86524x of SWX:SANN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86524x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CHF) x Listing Adjustment Factor
= CHF 1,002.00 x 0.86524
€866.97
Value per share (EUR) From above. €866.97
Current discount Discount to share price of €13.74
= -1 x (€13.74 - €866.97) / €866.97
98.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Santhera Pharmaceuticals Holding is available for.
Intrinsic value
>50%
Share price is €13.74 vs Future cash flow value of €866.97
Current Discount Checks
For Santhera Pharmaceuticals Holding to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Santhera Pharmaceuticals Holding's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Santhera Pharmaceuticals Holding's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Santhera Pharmaceuticals Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Santhera Pharmaceuticals Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:S3F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CHF CHF-9.07
SWX:SANN Share Price ** SWX (2019-04-18) in CHF CHF15.88
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Santhera Pharmaceuticals Holding.

DB:S3F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:SANN Share Price ÷ EPS (both in CHF)

= 15.88 ÷ -9.07

-1.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Santhera Pharmaceuticals Holding is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Santhera Pharmaceuticals Holding is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Santhera Pharmaceuticals Holding's expected growth come at a high price?
Raw Data
DB:S3F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
58.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Santhera Pharmaceuticals Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Santhera Pharmaceuticals Holding's assets?
Raw Data
DB:S3F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CHF CHF0.74
SWX:SANN Share Price * SWX (2019-04-18) in CHF CHF15.88
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:S3F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:SANN Share Price ÷ Book Value per Share (both in CHF)

= 15.88 ÷ 0.74

21.4x

* Primary Listing of Santhera Pharmaceuticals Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Santhera Pharmaceuticals Holding is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Santhera Pharmaceuticals Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Santhera Pharmaceuticals Holding has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Santhera Pharmaceuticals Holding expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Santhera Pharmaceuticals Holding expected to grow at an attractive rate?
  • Santhera Pharmaceuticals Holding's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Santhera Pharmaceuticals Holding's earnings growth is expected to exceed the Germany market average.
  • Santhera Pharmaceuticals Holding's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:S3F Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:S3F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 58.2%
DB:S3F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 58%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:S3F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:S3F Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 506 293 417 2
2022-12-31 297 135 198 2
2021-12-31 66 3 -11 1
2020-12-31 74 -46 -53 2
2019-12-31 36 -56 -61 2
2018-12-31 31 -46 -54 2
DB:S3F Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2018-09-30 30 -41 -58
2018-06-30 28 -42 -56
2018-03-31 26 -41 -54
2017-12-31 23 -40 -52
2017-09-30 22 -39 -42
2017-06-30 23 -33 -40
2017-03-31 21 -30 -38
2016-12-31 19 -27 -35
2016-09-30 15 -28 -21
2016-06-30 10 -29 -6
2016-03-31 7 -25 0
2015-12-31 4 -22 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Santhera Pharmaceuticals Holding's earnings are expected to grow significantly at over 20% yearly.
  • Santhera Pharmaceuticals Holding's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:S3F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Santhera Pharmaceuticals Holding Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:S3F Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 63.81 63.81 63.81 1.00
2022-12-31 30.37 30.37 30.37 1.00
2021-12-31 -0.02 0.62 -0.66 2.00
2020-12-31 -5.57 -1.34 -9.80 2.00
2019-12-31 -6.78 -2.34 -11.22 2.00
2018-12-31 -7.85 -6.89 -8.80 2.00
DB:S3F Past Financials Data
Date (Data in CHF Millions) EPS *
2018-09-30 -9.07
2018-06-30 -8.85
2018-03-31 -8.53
2017-12-31 -8.22
2017-09-30 -6.71
2017-06-30 -6.39
2017-03-31 -6.02
2016-12-31 -5.65
2016-09-30 -3.35
2016-06-30 -0.94
2016-03-31 0.03
2015-12-31 1.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Santhera Pharmaceuticals Holding is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Santhera Pharmaceuticals Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Santhera Pharmaceuticals Holding has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Santhera Pharmaceuticals Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Santhera Pharmaceuticals Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Santhera Pharmaceuticals Holding does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Santhera Pharmaceuticals Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Santhera Pharmaceuticals Holding's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Santhera Pharmaceuticals Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Santhera Pharmaceuticals Holding Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:S3F Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 30.23 -58.12 43.39 35.49
2018-06-30 28.11 -56.17 45.18 33.71
2018-03-31 25.53 -53.85 44.06 30.14
2017-12-31 22.94 -51.53 42.94 26.56
2017-09-30 22.26 -42.06 37.70 22.96
2017-06-30 22.68 -40.16 35.16 21.28
2017-03-31 20.86 -37.79 33.01 19.48
2016-12-31 19.03 -35.42 30.86 17.68
2016-09-30 14.55 -20.53 28.61 16.21
2016-06-30 10.08 -5.64 26.36 14.74
2016-03-31 7.20 0.15 21.48 12.13
2015-12-31 4.32 5.95 16.60 9.51
2015-09-30 3.77 -2.64 12.15 8.17
2015-06-30 3.22 -11.24 7.70 6.83
2015-03-31 2.90 -9.60 6.34 6.35
2014-12-31 2.59 -7.95 4.98 5.88
2014-09-30 1.81 -6.79 4.08 4.40
2014-06-30 1.02 -5.62 3.18 2.92
2014-03-31 1.17 -5.69 3.61 3.54
2013-12-31 1.32 -5.76 4.04 4.16
2013-09-30 2.14 -17.48 4.60 5.17
2013-06-30 2.97 -29.21 5.17 6.17
2013-03-31 3.25 -30.33 5.55 6.35
2012-12-31 3.54 -31.45 5.92 6.53
2012-09-30 3.44 -24.85 6.38 9.47
2012-06-30 3.34 -18.29 6.85 12.51

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Santhera Pharmaceuticals Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Santhera Pharmaceuticals Holding has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Santhera Pharmaceuticals Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Santhera Pharmaceuticals Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Santhera Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Santhera Pharmaceuticals Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Santhera Pharmaceuticals Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Santhera Pharmaceuticals Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Santhera Pharmaceuticals Holding's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Santhera Pharmaceuticals Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Santhera Pharmaceuticals Holding Company Filings, last reported 6 months ago.

DB:S3F Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 4.80 54.19 25.39
2018-06-30 15.18 53.83 34.82
2018-03-31 15.18 53.83 34.82
2017-12-31 32.26 53.11 58.21
2017-09-30
2017-06-30 55.20 52.43 77.97
2017-03-31 55.20 52.43 77.97
2016-12-31 74.35 0.00 49.82
2016-09-30 74.35 0.00 49.82
2016-06-30 89.19 0.00 63.56
2016-03-31 89.19 0.00 63.56
2015-12-31 106.25 0.00 76.86
2015-09-30 106.25 0.00 76.86
2015-06-30 11.88 0.00 10.48
2015-03-31 11.88 0.00 10.48
2014-12-31 17.32 0.00 17.44
2014-09-30 17.32 0.00 17.44
2014-06-30 6.74 0.00 5.04
2014-03-31 6.74 0.00 5.04
2013-12-31 7.11 0.00 5.04
2013-09-30 7.11 0.00 5.04
2013-06-30 8.98 0.00 7.57
2013-03-31 8.98 0.00 7.57
2012-12-31 11.37 2.21 12.28
2012-09-30 11.73 2.21 12.28
2012-06-30 37.39 2.22 16.23
  • Santhera Pharmaceuticals Holding's level of debt (1128.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1128.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Santhera Pharmaceuticals Holding has less than a year of cash runway based on current free cash flow.
  • Santhera Pharmaceuticals Holding has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.6% each year.
X
Financial health checks
We assess Santhera Pharmaceuticals Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Santhera Pharmaceuticals Holding has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Santhera Pharmaceuticals Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Santhera Pharmaceuticals Holding dividends. Estimated to be 0% next year.
If you bought €2,000 of Santhera Pharmaceuticals Holding shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Santhera Pharmaceuticals Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Santhera Pharmaceuticals Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:S3F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:S3F Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Santhera Pharmaceuticals Holding has not reported any payouts.
  • Unable to verify if Santhera Pharmaceuticals Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Santhera Pharmaceuticals Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Santhera Pharmaceuticals Holding has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Santhera Pharmaceuticals Holding's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Santhera Pharmaceuticals Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Santhera Pharmaceuticals Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Santhera Pharmaceuticals Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Santhera Pharmaceuticals Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Meier
COMPENSATION CHF0
AGE 56
TENURE AS CEO 7.5 years
CEO Bio

Dr. Thomas Meier, Ph.D., has been the Chief Executive Officer of Santhera Pharmaceuticals Holding AG since October 1, 2011 and also serves as its Head of Executive Management Team. Dr. Meier served as the Chief Scientific Officer of Santhera Pharmaceuticals until October 1, 2011. He serves as a Director of Santhera Pharmaceuticals Holdi since April 4, 2017. He is a reputed neuroscientist and was the founder and Chief Executive Officer of MyoContract AG. As a senior scientist with a distinguished track record in the field of neuromuscular research, Dr. Meier directed all of MyoContract's activities. Dr. Meier became an independent research group leader and lecturer at the Department of Pharmacology & Neurobiology at the Biozentrum of the University of Basel, where he established MyoContract. During his successful career, he has produced several high-impact papers in the field of neuromuscular differentiation. Dr. Meier has won the International Research Fellowship Award from the NIH, USA and has received a long-term fellowship from the Human Frontier Science Foundation. In 2007, he received the BioValley Basel Award for his outstanding contributions to the life sciences in the area. Dr. Meier studied Biology and Neurosciences in Erlangen (Germany), Geneva and Basel where he received his Ph.D. from the University of Basel in 1992 and subsequently joined the University of Colorado Health Sciences Center, USA. In 1999.

CEO Compensation
  • Insufficient data for Thomas to compare compensation growth.
  • Thomas's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Santhera Pharmaceuticals Holding management team in years:

4.2
Average Tenure
57
Average Age
  • The tenure for the Santhera Pharmaceuticals Holding management team is about average.
Management Team

Thomas Meier

TITLE
CEO, Head of Executive Management Team & Director
AGE
56
TENURE
7.5 yrs

Kristina Nygren

TITLE
Executive VP
COMPENSATION
CHF1M
AGE
57
TENURE
2.3 yrs

Christoph Rentsch

TITLE
Chief Financial Officer
AGE
59
TENURE
3.8 yrs

Oliver Strub

TITLE
Executive VP
AGE
55
TENURE
4.2 yrs

Günther Metz

TITLE
Executive Vice President of Business Development
AGE
60
TENURE
4.2 yrs
Board of Directors Tenure

Average tenure and age of the Santhera Pharmaceuticals Holding board of directors in years:

2
Average Tenure
55
Average Age
  • The average tenure for the Santhera Pharmaceuticals Holding board of directors is less than 3 years, this suggests a new board.
Board of Directors

Elmar Schnee

TITLE
Chairman
COMPENSATION
CHF264K
AGE
59
TENURE
2 yrs

Thomas Meier

TITLE
CEO, Head of Executive Management Team & Director
AGE
56
TENURE
2 yrs

Martin Gertsch

TITLE
Vice Chairman
COMPENSATION
CHF297K
AGE
53

Patrick Vink

TITLE
Director
COMPENSATION
CHF195K
AGE
55
TENURE
2 yrs

Philipp Gutzwiller

TITLE
Director
COMPENSATION
CHF186K
AGE
50
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Santhera Pharmaceuticals Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Santhera Pharmaceuticals Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for orphan and other diseases with high unmet medical needs in the European countries. The company’s portfolio comprises clinical stage and marketed treatments for neuroophthalmologic, neuromuscular, and pulmonary diseases. Its pipeline product, idebenone, is in Phase III clinical stage for the treatment of Duchenne muscular dystrophy. The company commercializes idebenone under the Raxone name in 20 countries. Its pipeline also includes omigapil, an investigational drug with anti-apoptotic properties in development to address unmet medical needs for patients with congenital muscular dystrophy; and POL6014, a clinical stage selective inhibitor of human neutrophil elastase to treat cystic fibrosis and other lung diseases. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.

Details
Name: Santhera Pharmaceuticals Holding AG
S3F
Exchange: DB
Founded:
CHF147,738,702
10,608,459
Website: http://www.santhera.com
Address: Santhera Pharmaceuticals Holding AG
Hohenrainstrasse 24,
Pratteln,
Basel-Landschaft, 4133,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX SANN Registered Shares SIX Swiss Exchange CH CHF 03. Nov 2006
OTCPK SPHD.F Registered Shares Pink Sheets LLC US USD 03. Nov 2006
DB S3F Registered Shares Deutsche Boerse AG DE EUR 03. Nov 2006
LSE 0QN1 Registered Shares London Stock Exchange GB CHF 03. Nov 2006
BATS-CHIXE SANNZ Registered Shares BATS 'Chi-X Europe' GB CHF 03. Nov 2006
Number of employees
Current staff
Staff numbers
106
Santhera Pharmaceuticals Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:01
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2018/12/12
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.